BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Greene MK, Johnston MC, Scott CJ. Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance. Cancers (Basel) 2021;13:6175. [PMID: 34944794 DOI: 10.3390/cancers13246175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Sakamoto K, Qi Y, Miyako E. Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors. Sci Rep 2023;13:518. [PMID: 36627374 DOI: 10.1038/s41598-023-27825-8] [Reference Citation Analysis]
2 Elzoghby AO, Ferrone CR, Ferrone S, Nasr ML. Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy. Drug Discov Today 2023;28:103434. [PMID: 36368630 DOI: 10.1016/j.drudis.2022.103434] [Reference Citation Analysis]
3 Barui S, Percivalle NM, Conte M, Dumontel B, Racca L, Carofiglio M, Cauda V. Development of doped ZnO-based biomimicking and tumor-targeted nanotheranostics to improve pancreatic cancer treatment. Cancer Nano 2022;13:37. [DOI: 10.1186/s12645-022-00140-z] [Reference Citation Analysis]
4 Brero F, Gallo S. Nanomaterials in Cancer Diagnosis and Therapy. Int J Mol Sci 2022;23. [PMID: 36430246 DOI: 10.3390/ijms232213770] [Reference Citation Analysis]
5 Dennahy IS, Han Z, Maccuaig WM, Chalfant HM, Condacse A, Hagood JM, Claros-sorto JC, Razaq W, Holter-chakrabarty J, Squires R, Edil BH, Jain A, Mcnally LR. Nanotheranostics for Image-Guided Cancer Treatment. Pharmaceutics 2022;14:917. [DOI: 10.3390/pharmaceutics14050917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]